Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), is a clinical-stage biopharmaceutical company focused on discovery, development and commercialization of therapies for ocular diseases. The Company’s lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development.
Inotek recently announced financial results and business progress for the fiscal year ended December 31, 2016, along with operational highlights for the company. Net loss was $42.9 million for the year ended December 31, 2016, compared to $68.0 million for the year ended December 31, 2015, which included $42.8 million in non-cash expenses.
The management confirmed that they intend to discuss full MATrX-1 data set with the US Food and Drug Administration in the first half of 2017 to determine next steps for the clinical development of the monotherapy program.
It was further confirmed that a Phase 2 fixed-dose combination study of trabodenoson with latanoprost, addressing a considerably larger market opportunity than monotherapy, is fully enrolled now and the company expect to report top-line data in mid-2017. Based on the results of this trial, it will then determine next steps for the clinical development of this combination therapy.
***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP – SMS/text alert service for free, simply text the word “Traders” to the phone number “25827” from your cell phone***
Notwithstanding these positive developments, the company continues to remain exposed to risk associated with pre-development phase. In fact, it already experienced a setback in the recent past. Trabodenoson did not achieve statistically significant results in their monotherapy trial in January 2017. The reason for failure is being contributed to a few outliers at certain clinical trial sites & upon news of this failed trial; the stock prices declined over 70%. Therefore, future trials could also produce negative results, and the company may receive unfavorable news from the FDA, which could significantly constrain its business risk profile.
About the Company:
Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company’s lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development. Trabodenoson was developed in Inotek’s laboratories and is designed to restore the eye’s natural pressure control mechanism. Additionally, the Company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases.
Inotek’s value drivers:
Glaucoma overview & potential market size: Glaucoma is a disease of the eye in which damage to the optic nerve leads to progressive, irreversible vision loss. Its characteristics can include structural evidence of optic nerve damage, vision loss and consistently elevated IOP.
According to IMS Health, sales of glaucoma drugs in 2013 were approximately $2.0 billion in the United States and $5.6 billion worldwide and 31.2 million prescriptions were written for glaucoma medications in the United States. According to IMS Health, approximately two-thirds of these prescriptions were for generic drugs, including latanoprost and timolol, which are the top two selling drugs for the treatment of glaucoma. Due to the lack of innovation in medications for glaucoma, most of the drugs used to treat glaucoma are generic drugs. IMS Health projects U.S. sales of glaucoma drugs to be $3.1 billion in 2018, an increase of approximately 54% over 2013 sales.
The ITEK management believe that trabodenoson’s IOP-lowering results, complementary mechanism of action, dosing and safety profile make it well suited for use in an FDC with a PGA, which could be a convenient option for patients currently using two or more glaucoma drugs to lower IOP.
Recent Trabodenoson Development Program Highlights:
- In January 2017, Inotek announced top-line results of MATrX-1, a Phase 3 randomized, double-masked, placebo-controlled trial of trabodenoson for the treatment of primary open-angle glaucoma or ocular hypertension. The trial did not achieve its primary endpoint, which was superiority in reduction of IOP compared with placebo at every single one of the 12 time points.
- In July 2016, Inotek initiated a Phase 2 dose-ranging trial of a fixed-dose combination of trabodenoson and latanoprost in patients with ocular hypertension or primary open-angle glaucoma. Top-line results from this study are expected in mid-2017.
- In July 2016, Inotek announced the issuance of a U.S. composition of matter patent for the combination of trabodenoson with a prostaglandin analog for the treatment of IOP in patients with glaucoma.
- Report top-line Phase 2 fixed-dose combination dose-ranging trial data in mid-2017.
- Complete analysis of MATrX-1 study results and determine next steps.
Key risk factors and potential stock drivers:
The company’s prospects are dependent on successful completion of clinical development and regulatory approval, for its product candidates, including trabodenoson monotherapy and trabodenoson with latanoprost as a fixed-dose combination, or FDC. Therefore, it is exposed to numerous risks and uncertainties associated with product development.
The movements in stock price of a product development stage company like Inotek, is highly volatile & speculative because it entails substantial upfront expenditures and significant risk that a product candidate will fail to gain regulatory approval or become commercially viable.
The company is expected to continue to incur significant and increasing operating losses and negative cash flows for the foreseeable future. These losses have, had and will continue to have a material adverse effect on its stockholders’ deficit, financial position, cash flows and working capital.
The company would need to obtain additional financing to fund operations and, any inability to obtain such financing; it may be unable to complete the development and commercialization of its primary product candidates.
Inotek’s operations have consumed substantial amounts of cash since inception & additional capital, which it might need to operate or expand business, may not be available. Therefore, it may not have sufficient cash to service its debt in a timely manner.
Inotek has not generated any revenue from product sales since inception and does not expect to generate any revenue from the sale of products soon. Its ability to generate revenues will depend on the successful development, regulatory approval and commercialization of trabodenoson and any other future product candidates.
- Loss from operations was $41.9 million for the year ended December 31, 2016, compared to $20.4 million for the year ended December 31, 2015.
- Net loss was $42.9 million for the year ended December 31, 2016, compared to $68.0 million for the year ended December 31, 2015, which included $42.8 million in non-cash expenses associated with marking the 2020 Convertible Notes derivative liability to market value at the time of the note conversions.
Cash Flow & Balance Sheet:
Inotek has a history of losses and management anticipates that it will continue to incur net losses for the foreseeable future. Its net losses were $42.9 million; $68.0 million and $9.5 million for the years ended December 31, 2016, 2015 and 2014, respectively.
As of December 31, 2016, it had an accumulated deficit of $238.9 million with approximately 27.0 million shares of common stock outstanding at December 31, 2016.
In August 2016, Inotek closed an underwritten public offering of $52.0 million aggregate principal amount of 5.75% Convertible Senior Notes due 2021 and received net proceeds of approximately $48.7 million after deducting underwriting discounts and offering-related costs.
As of December 31, 2016, it had $126.5 million of cash and cash equivalents and short-term investments. This is estimated to be sufficient to sustain operations into 2019.
On Friday, March 31, 2017, Inotek shares declined by -6.9% to $2.0 on an average volume of 1.4 million shares exchanging hands. Market capitalization is $50.2 million. The current RSI is 60.47
In the past 52 weeks, shares of Inotek have traded as low as $1.5 and as high as $10.90.
At $2.0, shares of Inotek are trading above its 50-day moving average (MA) at $1.67 and below its 200-day MA at $5.69.
The present support and resistance levels for the stock are at $1.90 & $2.10 respectively.
About Traders News Source:
Big Opportunities in Small Cap’s
Traders News Source recent profiles and track record, 534% in verifiable potential gains for our members on 3 small cap alerts alone!
January 31st, 2017 (NASDAQ: HIMX) opened at $5.10/share and hit a high of $9.68/share March 24th, 2017 for gains of 89% within 60 days- http://finance.yahoo.com/news/himax-technologies-review-4q-2016-130000319.html
February 6th, 2017- (NASDAQ: SCON) opened at $1.12/share hit a high of $1.80/share within 10 days our member potential gains- 60% – http://finance.yahoo.com/news/superconductor-technologies-potential-revolutionize-smart-130000844.html
March 6th, 2017 (OTC: USRM) opened at .035/share and hit over .17/share within 25 days for gains of 385% for our members- http://finance.yahoo.com/news/traders-news-issues-comprehensive-report-130000743.html
These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So, if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.
We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.
Traders News Source Mission Statement
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Traders News Source has not been compensated for this report by anyone and the opinions if any are that of the author Vikas Agrawal, CFA. Author’s Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I, wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in the article.
This web site, published by TNS LLC, and is an investment newsletter that is built on the premise of assisting individual investors in learning about investing. Our goal as publishers of financial information is to provide research and analysis of investments to our subscribers. TNS LLC does not give buy or sell recommendations. We do purchase distribution rights from analyst, financial writers and bloggers for a fee that may be licensed to issue price targets and recommendations. Furthermore, we encourage you to speak to a licensed professional prior to making an investment in any type of publicly traded security.
We do sell advertising to other companies including brokerage firms, web sites, publicly traded issuers, investor relations firms, and investment publications, among others. TNS LLC makes no warranty as to the policies of these organizations, and in no way endorses their offers, services, or the content of their advertisements.
When an advertiser is a publicly traded company or a third party acting on behalf of a public company, we fully disclose all compensation in the email advertisement. Such disclosure is included in a disclosure statement in each of the advertisements sent via email.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
PLEASE NOTE WELL: TNS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.
Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D.
TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur.
Understand there is no guarantee past performance will be indicative of future results. In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.